Spring Bank Pharmaceuticals Inc

Spring Bank Pharmaceuticals — F-star Therapeutics — FY2020 Earnings Presentation

10 slides from Spring Bank Pharmaceuticals's earnings presentation, Apr 5, 2021

  1. Slide 1: Full-Year 2020 Financial Results and Corporate Update

    Next Generation Immunotherapies. Overcoming Cancer. Full-Year 2020 Financial Results and Corporate Update 29th March 2021

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Lit

  3. Slide 3: Our Mission

    Our Mission We are dedicated to developing next generation immunotherapies to transform the lives of patients with cancer

  4. Slide 4: A Time of Transformation for F-star

    A Time of Transformation for F-star Q4 2020 ✓Acceleration into the clinic—despite COVID pandemic ✓Completed NASDAQ listing (FSTX) – November 2020 ✓FS118 bispecific designed to rescue Checkpoint Inhibitor (CPI) treatment failures: Phase 1 readout ✓FS120 dual agonist bispecific designed to improve out

  5. Slide 5: Our Next Generation Bispecifics to Activate the Immune System

    Our Next Generation Bispecifics to Activate the Immune System Tetravalent mAb2 bispecifics Natural human antibody means easier manufacturing and favorable safety Targeted enhanced bispecific activity through four binding sites (tetravalent) eptor clustering drives stronger biological potency than ot

  6. Slide 6: Next Generation Immunotherapies: Clinical Stage Programs

    Next Generation Immunotherapies Clinical Current Status Targets Opportunity Clinical Stage Programs Preclinical Ph1 Ph2 Rescuing CPI Q1 2021 US Phase 2 in PD-1 resistant FS118 LAG-3/PD-L1 treatment failures head & neck cancer patients Improving outcomes FS222 CD137/PD-L1 European Phase 1 trial in PD

  7. Slide 7: Anticipated Future Data Milestones

    Anticipated Future Data Milestones FS118 Update on phase 2 PoC FS118 Completion trial in PD-(L)1 acquired of PoC trial resistance patients Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 FS120 Update on FS120 Safety & biomarker FS120 Update on accelerated dose update to support initi

  8. Slide 8: 2020 Financial Results: Statement of Operations

    2020 Financial Results F-star Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss (in thousands, except share and per share data) Year Ended December 31 2020 2019 License revenue $ 11,256 $ 28,321 Operating expenses: Research and development 14,128 31,386 General

  9. Slide 9: 2020 Financial Results: Balance Sheets

    2020 Financial Results F-star Therapeutics, Inc. Condensed Consolidated Balance Sheets (in thousands) December 31, 2020 2019 Cash and cash equivalents $ 18,526 $ 4,901 Prepaid and other current assets 7,539 14,120 Other assets 37,544 19,457 Total assets $ 63,609 $ 38,478 Accounts payable and other c

  10. Slide 10: Our Mission - Thank you

    Our Mission We are dedicated to developing next generation immunotherapies to transform the lives of patients with cancer Thank you

F-star Therapeutics — FY2020 Earnings Presentation on 6ix